parexel international corp
(PRXL:Consolidated Issue Listed on Nasdaq Glbl Slct Mrkt)
parexel international corp (PRXL) Snapshot
|
Open
$46.90
|
Previous Close
$46.83
|
|
|
Day High
$47.18
|
Day Low
$46.50
|
|
|
52 Week High
05/15/13 - $47.23
|
52 Week Low
05/21/12 - $25.12
|
|
|
Market Cap
2.7B
|
Average Volume 10 Days
594.5K
|
|
|
EPS TTM
$1.47
|
Shares Outstanding
56.8M
|
|
|
EX-Date
--
|
P/E TM
31.8x
|
|
|
Dividend
--
|
Dividend Yield
--
|
parexel international corp (PRXL) Latest News
parexel international corp (PRXL) Related Businessweek News
No Related Businessweek News Foundparexel international corp (PRXL) Details
PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics (Perceptive). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. This segment manages various aspects of clinical trials, including study and protocol design, case report form design, paper or electronic questionnaires design, patient enrollment, study monitoring and data collection, data analysis, report writing, and medical services. The PCMS segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, and good manufacturing practice compliance consulting; and market development, product development, and targeted communications services in support of product launch. Its consultants also identify alternatives and propose solutions to address clients’ product development, registration, and commercialization issues. In addition, this segment provides reimbursement and market access services. The Perceptive segment provides information technology solutions comprising medical imaging and systems integration services; ClinPhone RTSM, CTMS, and DataLabs EDC products; Web-based portals; and patient diary applications. The company was founded in 1983 and is headquartered in Waltham, Massachusetts.
parexel international corp (PRXL) Top Compensated Officers
parexel international corp (PRXL) Key Developments
PAREXEL International Corporation reported unaudited consolidated earnings results for third quarter and nine months ended March 31, 2013. For the quarter, the company’s total revenue was $523,451,000 against $412,029,000 a year ago. Income from operations was $36,606,000 against $28,217,000 a year ago. Income before income tax was $35,833,000 against $21,942,000 a year ago. Net income was $29,524,000 or $0.50 per diluted share against $22,869,000 or $0.38 per basic and diluted share a year ago. On Non-GAAP basis, the company’s income from operations was $37,320,000 against $37,320,000 a year ago. Income before income tax was $36,640,000 against $23,749,000 a year ago. Net income was $29,465,000 or $0.50 per diluted share against $19,862,000 or $0.33 per diluted share a year ago. Capital expenditures were $18,741,000 against $10,650,000 a year ago. Cash flow generated by operations totaled $53.6 million. For the nine months, the company’s total revenue was $1,469,108,000 against $1,160,489,000 a year ago. Income from operations was $97,795,000 against $63,263,000 a year ago. Income before income tax was $94,425,000 against $54,818,000 a year ago. Net income was $65,931,000 or $1.10 per diluted share against $45,370,000 or $0.75 per diluted share a year ago. On Non-GAAP basis, the company’s income from operations was $99,248,000 against $68,932,000 a year ago. Income before income tax was $95,576,000 against $60,487,000 a year ago. Net income was $71,448,000 or $1.19 per diluted share against $45,459,000 or $0.75 per diluted share a year ago. The company provided earnings guidance for the fiscal fourth quarter of 2013. For the period, the company expects revenue to be $449.0 million to $459.0 million. GAAP EPS to be $0.40 to $0.44. The company expects the GAAP tax rate for the fourth quarter to be in the 30% range. The company revised earnings guidance for the fiscal year 2013. The company expects revenue to be $1,720.0 billion to $1,730.0 billion against previous guidance of $1.695 billion to $1.710 billion. GAAP EPS to be $1.51 to $1.55 against previous guidance of $1.39 to $1.47. Adjusted diluted EPS to be $1.60 to $1.64 against previous guidance of $1.48 to $1.56. The company expects the GAAP tax rate for the fiscal year 2013 to be approximately 27% 28%. Earnings per share growth in the range of 44% to 48%. The company continue to expect capital expenditures to be in the $75 million to $80 million range for the full fiscal year, and free cash flow is estimated to be in the range of $120 million to $130 million for fiscal year 2013.
PAREXEL International Corporation, Q3 2013 Earnings Call, May 01, 2013
PAREXEL International Corporation announced that they will report Q3, 2013 results at 5:00 PM, Eastern Standard Time on Apr 30, 2013
| Recently Viewed | |||
| PRXL:US | $46.71 USD | -0.12 | |
| Company | Last | Change |
| Charles River Laboratories International Inc | $45.01 USD | -0.12 |
| Covance Inc | $77.33 USD | +0.45 |
| ICON PLC | $33.38 USD | +0.47 |
| Nordion Inc | C$7.48 CAD | +0.12 |
| WuXi PharmaTech Cayman Inc | $20.43 USD | +0.11 |
| View Industry Companies | ||
Industry Analysis
PRXL
Industry Average
| Valuation | PRXL | Industry Range |
| Price/Earnings | 33.7x |
|
| Price/Sales | 1.6x |
|
| Price/Book | 4.8x |
|
| Price/Cash Flow | 17.6x |
|
| TEV/Sales | 1.2x |
|
Post a JobJobs
- Billerica, MA | PAREXEL InternationalPosted: May 09
- Billerica, MA | PAREXELPosted: May 15
- Horsham, PA | PAREXEL InternationalPosted: Apr 26
- Durham, NC | PAREXEL InternationalPosted: May 09
Sponsored Financial Commentaries
Sponsored Links
To contact PAREXEL INTERNATIONAL CORP, please visit www.parexel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








